The instructions for use and videos on how to take the trial medicine are now available online. Trial participants and care givers can access this information on this website in the “Clinical” trials section on the Resources Page
About the project
OligoG-pivotal-CF is a multinational clinical project to test the orphan drug OligoG CF-5/20 (OligoG) in a pivotal phase 2b clinical trial for the treatment of cystic fibrosis (CF). The project is funded by the H2020-SC1-2017-Two-Stage-RTD, topic SC1-PM-08-2017, and represents a new therapy for the rare disease cystic fibrosis (CF). The study drug OligoG CF-5/20 (OligoG) has received an EU Orphan Drug Medicinal Product Designation in 2007 and an FDA Orphan Drug Designation February 2016, both for the treatment of cystic fibrosis.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme part “Health, demographic change and well-being” (call H2020-SC1-2016-2017) under grant agreement No 755234.